Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED SEPTEMBER 2017. Refer to TA474: Sorafenib for treating advanced hepatocellular carcinoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | sorafenib (Nexavar®) | ||
| Formulation | 200 mg film-coated tablet | ||
| Reference number | 284 | ||
| Indication | Treatment of hepatocellular carcinoma |
||
| Company | Bayer Healthcare Pharmaceuticals | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 0616 | ||
| NMG meeting date | 10/02/2016 | ||
| AWMSG meeting date | 23/03/2016 | ||
| Ratification by Welsh Government | 05/04/2016 | ||
| Date of issue | 12/04/2016 | ||
| NICE guidance | TA474: Sorafenib for treating advanced hepatocellular carcinoma (external website - opens in new window) |
||
| Further information |
|||